Event Videos
http://www.ncbi.nlm.nih.gov/pubmed/24843060 Middleman AB, Baker CJ, Kozinetz CA, Kamili S, Nguyen C, Hu DJ, Spradling PR. Duration of protection after infant hepatitis B vaccination series. Pediatrics.2014 Jun; 133(6): e1500-7. Abstract BACKGROUND: METHODS: Published on:
Jun-2014
|
http://www.ncbi.nlm.nih.gov/pubmed/24288032 Amatya P, Shah D, Gupta N, Bhatta NK. Clinical and ultrasonographic measurement of liver size in normal children. Indian J Pediatr. 2014 May; 81(5):441-5. To measure the normal range of dimensions of liver in children of various age groups and to compare the liver measurement obtained by palpation-percussion, auscultation and ultrasonography. Published on:
May-2014
|
http://www.ncbi.nlm.nih.gov/pubmed/24509302 Mandal S, Miraglia R, Maruzzelli L, Liotta R, Tuzzolino F, Spada M, Riva S, Luca A. US guided percutaneous liver biopsy in pediatric liver transplant recipients. J Pediatr Gastroenterol Nutr. 2014 Jun; 58(6): 756-61. Abstract OBJECTIVES: METHODS: Published on:
Jun-2014
|
http://www.ncbi.nlm.nih.gov/pubmed/23884647 Alam S, Khanna R, Mukund A. Clinical and prothrombotic profile of hepatic vein outflow tract obstruction. Indian J Pediatr. 2014 May; 81(5):434-40. Abstract To study the clinical as well as prothrombotic profile and outcome of hepatic venous outflow tract obstruction in children This is a prospective st.udy of a cohort of hepatic venous outflow tract obstruction (HVOTO) pediatric cases. All children and adolescents presenting with acute or chronic liver disease were screened for HVOTO with ultrasound and Doppler imaging and confirmed by multi-detector computerised tomography (MDCT) with contrast enhancement. Published on:
May-2014
|
http://www.ncbi.nlm.nih.gov/pubmed/24552673 Tutar O, Beşer ÖF, Adaletli I, Tunc N, Gulcu D, Kantarci F, Mihmanli I, Cokugras FC, Kutlu T, Ozbay G, Erkan T. Shear wave elastography in the evaluation of liver fibrosis in children. J Pediatr Gastroenterol Nutr. 2014 Jun; 58(6): 750-5. Abstract BACKGROUND: METHODS: Published on:
Jun-2014
|
http://www.ncbi.nlm.nih.gov/pubmed/24792633 Bakula A, Socha P, Klaudel-Dreszler M, Karolczyk G, Wozniak M, Rutynowska-Pronicka O, Matysiak M. Giant cell hepatitis with autoimmune haemolytic anemia in children: proposal for therapeutic approach. J Pediatr Gastroenterol Nutr. 2014 May; 58(5):669-73. Giant cell hepatitis (GCH) with autoimmune hemolytic anemia (AIHA) is a rare, progressive disorder in infants and young children. The disease is aggressive and may lead to liver or multi organ failure with fatal prognosis. Therapy with anti-CD20 monoclonal antibody, rituximab (Rtx), proved effective. The primary objective of the study was to evaluate therapy for severe GCH with AIHA. Published on:
May-2014
|
http://www.ncbi.nlm.nih.gov/pubmed/24827901 Howell J, Lemoine M, Thursz M. Prevention of materno-foetal transmission of hepatitis B in sub-Saharan Africa: the evidence, current practice and future challenges. J Viral Hepat. 2014 Jun; 21(6): 381-96. Abstract Published on:
Jun-2014
|
http://www.ncbi.nlm.nih.gov/pubmed/24345826 Oʼsullivan TA, Oddy WH, Bremner AP, Sherriff JL, Ayonrinde OT, Olynyk JK, Beilin LJ, Mori TA, Adams LA. Lower fructose intake may help protect against development of non-alcoholic Fatty liver in adolescents with obesity. J Pediatr Gastroenterol Nutr. 2014 May; 58(5): 624-31. Although obesity is a major risk factor for non-alcoholic fatty liver (NAFL), not all individuals with obesity develop the condition, suggesting that other factors such as diet may also contribute to NAFL development. We evaluated associations between fructose and total sugar intake and subsequent diagnosis of NAFL in adolescents with obesity and without obesity in a population-based cohort. Published on:
May-2014
|
http://www.ncbi.nlm.nih.gov/pubmed/24002804 Hsu C, Tsou HH, Lin SJ, Wang MC, Yao M, Hwang WL, Kao WY, Chiu CF, Lin SF, Lin J, Chang CS, Tien HF, Liu TW, Chen PJ, Cheng AL; Taiwan Cooperative Oncology Group. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective study. Hepatology. 2014 Jun; 59(6):2092-100. Abstract Published on:
Jun-2014
|
http://www.ncbi.nlm.nih.gov/pubmed/24325386 Hatamkhani S, Khalili H, Karimzadeh I, Dashti-Khavidaki S, Abdollahi A, Jafari S. Carnitine for prevention of antituberculosis drug-induced hepatotoxicity: a randomized, clinical trial. J Gastroenterol Hepatol. 2014 May; 29(5):997-1004. Abstract BACKGROUND AND AIM: In the present study, the potential benefits of oral carnitine in preventing antituberculosis drug-induced hepatotoxicity (ATDH) were evaluated. Published on:
May-2014
|